We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Novozymes Showcases Biopharmaceutical Solutions at BioProcess International 2010

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novozymes Showcases Biopharmaceutical Solutions at BioProcess International 2010"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Novozymes Biopharma, part of Novozymes A/S will be showcasing its portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA.

The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year's event Novozymes' booth will feature the company's range of regulatory compliant, recombinant and animal-free products and technologies.

During the five day conference, Novozymes will be presenting two technical posters entitled "Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics' and "Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production". In addition the company will deliver a presentation on the "Impact of recombinant albumin on the stability of a malarial antigen vaccine".

Novozymes will also be hosting a workshop on "Improving biomanufacturing efficiency through recombinant solutions". Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.

The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC, a member of the Sigma-Aldrich Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes' LONG R³IGF-I (LONGR3) growth factor.